World’s first mRNA lung cancer vaccine trials begin in Europe | Current Affairs | Vision IAS
News Today Logo

    World’s first mRNA lung cancer vaccine trials begin in Europe

    Posted 24 Aug 2024

    2 min read

    Vaccine BNT116 is designed to treat non-small cell lung cancer, the most common type of lung cancer

    • Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8million deaths every year.

    Vaccine is based on mRNA (messenger Ribonucleic Acid) technology.

    • This technology is seen as the next big phase of cancer treatment.

    About mRNA Vaccine Technology

    • Working Mechanism:
      • It works by introducing a piece of mRNA that corresponds to a viral protein, usually a small piece of a protein found on the virus’s outer membrane. 
        • mRNA is a genetic molecule that contains instructions or recipe that directs cells to make a protein using its natural machinery.
      • This mRNA prompts cells to create viral proteins, triggering the immune system to produce antibodies and boost the immune system.
        • E.g., the mRNA vaccine for COVID-19 directed cells to produce copies of a protein on the outside of the coronavirus known as the spike protein.
    • Benefits:  
      • Safer as it do not contain any live or weakened viruses.
      • Also, can be developed quickly, unlike other traditional vaccines, which can take months to produce by growing weakened forms of the virus. 
    • Tags :
    • mRNA Vaccine
    • Immune System
    • Non-Small Cell Lung Cancer
    Watch News Today
    Subscribe for Premium Features

    Quick Start

    Use our Quick Start guide to learn about everything this platform can do for you.
    Get Started